Navigation Links
Medivation Announces Third Quarter 2009 Financial Results Teleconference and Webcast on November 4, 2009
Date:10/28/2009

SAN FRANCISCO, Oct. 28 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that it will host a teleconference and webcast with management to discuss third quarter 2009 financial results and provide a general business update on Wednesday, November 4, 2009, at 4:30 p.m. Eastern Time. A press release for the third quarter ended September 30, 2009 will be released after markets close on November 4, 2009.

Interested parties may call 877-874-1563 from the U.S. or +1-719-325-4891 internationally. Individuals interested in listening to the live call via webcast may do so by visiting http://www.medivation.com. A replay of the webcast will be available on the Company's website for 30 days.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. In September 2008, Medivation announced a global agreement with Pfizer Inc to develop and commercialize dimebon (latrepirdine) for the treatment of Alzheimer's and Huntington diseases. With Pfizer, Medivation is conducting a broad dimebon clinical development program that includes several Phase 3 trials assessing the efficacy and safety of dimebon taken alone or in combination with other Alzheimer's medications in patients with mild, moderate and severe Alzheimer's disease. The companies are also conducting a Phase 3 trial of dimebon in Huntington disease. In October 2009, Medivation entered a global agreement with Astellas Pharma Inc. to develop and commercialize MDV3100 for prostate cancer. The first Phase 3 clinical trial in the MDV3100 development program, known as the AFFIRM trial, is under way in patients with castration-resistant prostate cancer who have previously been treated with docetaxel-based chemotherapy. For more information, please visit us at http://www.medivation.com.

SOURCE Medivation, Inc.


'/>"/>
SOURCE Medivation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Medivation Selected as Founding Member of New NASDAQ(R) NeuroInsights(R) Neurotech Index
2. Medivation Announces Participation in Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
3. Medivation Reports Year-End 2007 Financial Results and Pipeline Progress
4. Medivation Announces Senior Management Promotions
5. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients
6. Medivation Announces Presentation at the BMO Capital Markets 2008 Focus on Healthcare Conference on August 5
7. Medivation Announces Second Quarter 2008 Teleconference and Webcast on August 11, 2008
8. Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update
9. Medivation Announces Participation in Upcoming Conferences
10. Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Partnering Plans for Dimebon
11. Medivation Receives Corporate Achievement Award From Huntingtons Disease Society of America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... DC (PRWEB) , ... January 23, 2017 , ... ... organization that supports innovative science through unique partnerships, seeks outstanding early career nominees ... scientific innovation is critical to meeting the needs of a world in which ...
(Date:1/24/2017)... Jan. 23, 2017  Recognizing the need to ... discovery and solutions, the University of Miami announced ... for Science and Engineering to achieve those milestones ... to help solve some of the world,s most ... Julio Frenk unveiled the network of ...
(Date:1/24/2017)...  Today, the Fisher Center for Alzheimer,s Research Foundation ... study that could lead to the development of effective ... This groundbreaking research was conducted by the Fisher Center ... Dr. Paul Greengard , in the quest to ... Center scientists have linked a mutation that protects elderly ...
(Date:1/23/2017)... -- Spherix Incorporated (Nasdaq: SPEX ) an intellectual ... and monetization of intellectual property, today provided an update ... Anthony Hayes , Chief Executive Officer of Spherix, stated, ... with shareholders about the status of existing monetization efforts ... patent assets that fit with our current holdings.  We ...
Breaking Biology Technology:
(Date:1/11/2017)... , Jan. 11, 2017  Michael Johnson, co-founder of Visikol ... Capital Group, Inc., has been named to the elite "Forbes 30 ...  was one of 600 people in 20 fields nationwide to be ... of the 15,000 applicants were selected. ... He is currently a PhD candidate at Rutgers ...
(Date:1/4/2017)... VEGAS , Jan. 4, 2017  CES ... performance biometric sensor technology, today announced the launch ... sensor systems, the highly-accurate biometric sensor modules ... biometric technology, experience and expertise. The two ... Benchmark designed specifically for hearables, and Benchmark BW2.0, ...
(Date:12/20/2016)... 2016   Valencell , the leading innovator ... STMicroelectronics (NYSE: STM), a global semiconductor leader serving ... today the launch of a new, highly accurate ... includes ST,s compact SensorTile turnkey multi-sensor ... sensor system. Together, SensorTile and Benchmark deliver the ...
Breaking Biology News(10 mins):